Alternatives to PAIN Act

The Alternatives to PAIN Act, HR1227, amends Section 1860D-2 of the Social Security Act to modify Medicare Part D coverage for qualifying non-opioid pain management drugs. Starting January 1, 2026, these drugs will be exempt from deductibles and placed on the lowest cost-sharing tier. The bill also prohibits prior authorization and step therapy requirements for these specific medications. This directly increases patient access by reducing financial barriers and administrative hurdles, leading to higher utilization of non-opioid alternatives. The money trail for this bill involves a shift in Medicare Part D expenditures. While the bill does not appropriate new funds, it reallocates existing Part D spending by increasing the portion covered by Medicare plans and reducing beneficiary out-of-pocket costs. This effectively expands the addressable market for non-opioid pain drugs within the Medicare population. Pharmaceutical companies with FDA-approved non-opioid pain management drugs that meet the bill's criteria (non-opioid, FDA-approved for acute pain, no therapeutically equivalent generic) are positioned to capture this increased demand. This includes major pharmaceutical players like Pfizer ($PFE) with drugs such as Lyrica (though it has generics, specific formulations or new non-opioid approvals would qualify), Johnson & Johnson ($JNJ), AbbVie ($ABBV), Merck ($MRK), and GSK ($GSK) if they have or develop qualifying non-opioid pain treatments. Historically, legislation that reduces patient cost-sharing for specific drug categories has led to increased sales and revenue for manufacturers. For example, the Inflation Reduction Act of 2022, which included provisions to cap out-of-pocket drug costs for Medicare beneficiaries, was projected to increase utilization of certain high-cost drugs. While direct, comparable historical precedent for non-opioid specific cost-sharing reductions is limited, the general principle holds: reduced patient cost equals increased demand. The 82 cosponsors, including Republican Rep. Miller-Meeks and Democratic Rep. Barragan, indicate strong bipartisan support, increasing the likelihood of passage. Specific winners include pharmaceutical companies with proprietary non-opioid pain management drugs that meet the FDA criteria outlined in the bill. This could include companies developing novel non-opioid analgesics or those with existing branded products that lack therapeutically equivalent generics. Losers are less direct, but the shift away from opioids could marginally impact companies heavily invested in opioid pain management, though this bill's scope is limited to non-opioids. The bill is currently referred to the Committee on Energy and Commerce and the Committee on Ways and Means. Committee consideration and potential markups are the next steps, likely occurring in late 2025 or early 2026, with implementation targeted for January 1, 2026.